摘要
目的探讨影响阿替普酶静脉溶栓早期疗效的因素。方法回顾分析接受阿替普酶溶栓治疗的100例急性脑梗死患者临床数据，根据患者溶栓后24h美国国立卫生研究院神经功能缺损评分（NIHSS评分）减少是否〉3分，分为溶栓有效组和溶栓无效组，用单因素和多因素回归比较两组各临床数据的差异。结果单因素分析结果显示溶栓后早期疗效与3个月预后相关（P=0．000），logistic分析显示溶栓前收缩压与溶栓后早期疗效显著相关（OR1．031，95％CI1．008—1．056．P=0．009）。结论溶栓后早期疗效好者3个月的预后好。溶栓前收缩压低者的溶栓后早期疗效好。
Objective To analyze the factors affecting on early efficacy of intravenous thrombolysis with atleplase. Methods The clinical data of 100 acute cerebral infarction patients treated by intravenous thrombolysis with atleplase were retrospectively analyzed. The patients were divided into early effective group and ineffective group, which assessed by National Institute of Health Stroke Scale （NIHSS） with criteria of whether there were 〉 3 or not at 24 hours after therapy. Univariate analysis and multivariate logistic regression analysis were used to determine the differences of clinical data between the two groups. Results Univariate analysis revealed that the early improvement was significantly associated with favorable outcome at 3 month （ P = 0. 000 ） . Multivariate logistic analysis revealed that the systolic pressure at baseline was moderately positively associated with early improvement （ OR l. 031, 95% CI 1. 008-1. 056, P = 0. 009）. Conclusion Moderately lower baseline systolic pressure is associated with early improvement after thrombolytie therapy which is associated with ：favorable outcome at 3 month.
出处
《中华内科杂志》
CAS
CSCD
北大核心
2012年第10期781-783,共3页
Chinese Journal of Internal Medicine
关键词
脑梗死
组织型纤溶酶原激活物
预后
Brain infarction
Tissue plasminogen activator
Prognosis
